Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Final Results of BRIDGE Phase III Open-Label, Switch-Over Clinical Trial Evaluating Pegunigalsidase Alfa for the Treatment of Fabry Disease ...Middle East

CARMIEL, Israel and BOSTON, Dec. 30, 2020 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx®...

Read More Details
Finally We wish PressBee provided you with enough information of ( Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Final Results of BRIDGE Phase III Open-Label, Switch-Over Clinical Trial Evaluating Pegunigalsidase Alfa for the Treatment of Fabry Disease )

Also on site :

• Iconic Sitcom Actress, 67, Stuns With Ageless Appearance 20 Years After Show Ended
• Beloved ‘90s Icon Meets Iconic ‘Pitch Perfect’ Stars in an Unforgettable Red Carpet Moment
• 'Lightnin' Strikes' Singer Lou Christie Dies at 82, Leaving a Lasting Legacy